Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

GRIESEMER CHIROPRACTIC, LLC

NPI: 1598953317 · GREENWOOD, IN 46142 · Chiropractor · NPI assigned 10/05/2007

$3.24M
Total Medicaid Paid
91,339
Total Claims
76,433
Beneficiaries
42
Codes Billed
2018-01
First Month
2024-05
Last Month

Provider Details

Authorized OfficialGRIESEMER, MARK (DOCTOR, MEMBER, MANAGER)
NPI Enumeration Date10/05/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 18,211 $329K
2019 15,962 $642K
2020 19,447 $524K
2021 14,899 $656K
2022 12,387 $630K
2023 8,226 $355K
2024 2,207 $106K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 28,409 24,333 $828K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 17,198 14,828 $738K
J3300 Injection, triamcinolone acetonide, preservative free, 1 mg 9,881 6,726 $719K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 10,990 9,126 $309K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 11,619 10,517 $277K
76942 3,221 2,685 $94K
27096 1,664 1,392 $63K
20552 3,137 2,581 $62K
L0650 Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf 113 110 $61K
80361 966 860 $26K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 416 367 $18K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 854 516 $10K
72110 365 309 $8K
64483 52 50 $5K
20611 106 101 $3K
72170 251 210 $3K
93923 52 27 $3K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward 85 77 $2K
J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg 267 243 $2K
64493 79 65 $2K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 23 19 $2K
95923 15 15 $1K
95924 16 16 $1K
64484 26 25 $657.70
82962 918 772 $648.52
80347 24 24 $614.11
72050 25 18 $494.79
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 14 14 $415.28
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 73 53 $388.28
64494 41 28 $284.93
36415 Collection of venous blood by venipuncture 133 119 $265.50
64495 35 26 $180.30
96132 16 12 $147.73
20610 25 25 $128.58
96130 16 12 $113.97
93040 16 16 $78.41
80326 12 12 $67.50
96138 16 12 $50.76
80349 13 12 $33.75
80352 13 12 $33.75
Q4177 Floweramnioflo, 0.1 cc 130 55 $0.00
80365 14 13 $0.00